Dr. Ginna G. Laport, MD is a Hematology / Oncology Specialist - Hematologist (Blood) practicing in Stanford, CA
She has not yet shared a personalized biography with Doctor.com.
University | Degree | Focus | Graduated |
---|---|---|---|
U of Tx Medical School At Houston, Houston Tx | Other Degree | 1990 | |
University of Texas Medical School, Houston | Other Degree | 1990 |
Institution | Focus | Year |
---|---|---|
Internship - University of Chicago Hospitals | 1991 | |
Residency - University Of Chicago Hosps, Internal Medicine | Not Specified | |
Residency - University of Chicago Hospitals | 1993 | |
Fellowship - Stanford University School of Medicine,Stanford, Ca, United States | 1994 |
Certification | Cert. Body | Year |
---|---|---|
Internal medicine | Internal Medicine | Not Specified |
Position | Organization | Time |
---|---|---|
Professor of Medicine (Blood and Marrow Transplantation) | the Stanford University Medical Center | Present |
Publication | Publisher | Title | Published |
---|---|---|---|
Other Publication | Jourl of clinical oncology | Autologous or reduced | 2014 |
Other Publication | BRITISH JOURL OF HAEMATOLOGY | Autologous haematopoietic cell transplantation for non | 2013 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma | 2013 |
Other Publication | JOURL OF CLINICAL ONCOLOGY | Graft-Versus-Host Disease | 2013 |
Other Publication | Kate, A. S., Efron, B., Chhabra, S., Kohrt, H., Shizuru, J. A., Laport | Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid | 2013 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Alterte Donor Hematopoietic Cell Transplantation | 2012 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Follicular Lymphoma: Prognostic Factors, Conventiol Therapies | 2012 |
Other Publication | Hari, P., Pasquini, M. C., Logan, B. R., Stadtmauer, E. A., Krishn, A. | Immunoglobulin Free Light Chain (FLC) and Heavy Chain | 2011 |
Other Publication | JAMA-JOURL OF THE AMERICAN MEDICAL ASSOCIATION | Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning | 2011 |
Other Publication | HAEMATOLOGICA-THE HEMATOLOGY JOURL | Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment | 2011 |
Other Publication | BONE MARROW TRANSPLANTATION | Long-term outcomes in patients with high | 2011 |
Other Publication | ik, S. G., Negrin, R., Laport, G., Miklos, D., Shizuru, J., Arai, S., | Long-term outcomes of high-dose therapy using busulfan, etoposide | |
Other Publication | NEW ENGLAND JOURL OF MEDICINE | Protective conditioning for acute graft-versus-host disease | 2005 |
Other Publication | LEUKEMIA RESEARCH | Multiple unrelated clol abnormalities | 2004 |
Other Publication | JOURL OF HEMATOTHERAPY & STEM CELL RESEARCH | Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft | 2000 |
Other Publication | SEMIRS IN ONCOLOGY | The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma | 1998 |
Other Publication | SEMIRS IN ONCOLOGY | Treatment of adult acute lymphoblastic leukemia | 1997 |
Other Publication | Biology of blood and marrow transplantation | Total lymphoid irradiation-antithymocyte globulin conditioning | 2014 |
Other Publication | Journal of clinical oncology | Autologous or reduced | 2014 |
Other Publication | BLOOD | Prospective cohort study comparing intravenous busulfan to total body irradiation | 2013 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Simplified Validated Prognostic Model for Progression | 2013 |
Other Publication | BRITISH JOURNAL OF HAEMATOLOGY | Autologous haematopoietic cell transplantation for non | 2013 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma | 2013 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Impact of Pretransplantation Conditioning Regimens on Outcomes of Allogeneic Transplantation | 2013 |
Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Graft-Versus-Host Disease | 2013 |
Other Publication | Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H., Shizuru, J. A., Lapo | Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid | 2013 |
Other Publication | Benjamin, J., Chhabra, S., Kohrt, H., Laport, G. G., Arai, S., Johnsto | TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN | 2013 |
Other Publication | Benjamin, J., Chhabra, S., Kohrt, H. E., Laport, G. G., Arai, S., John | Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic | |
Other Publication | BLOOD | Conditioning regimens for allotransplants for diffuse large B-cell lymphoma | 2012 |
Other Publication | BONE MARROW TRANSPLANTATION | Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial | 2012 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Alternate Donor Hematopoietic Cell Transplantation | 2012 |
Other Publication | BLOOD | Prophylactic rituximab after allogeneic transplantation decreases B | 2012 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Tandem Transplantation for Follicular Lymphoma: The Best of Both Worlds? | 2012 |
Other Publication | BONE MARROW TRANSPLANTATION | Tandem chemo-mobilization followed by high | 2012 |
Other Publication | BONE MARROW TRANSPLANTATION | Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative | 2012 |
Other Publication | Hematology / the Education Program of the American Society of Hematolo | Changing role of stem cell transplantation in follicular lymphoma. | 2012 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Follicular Lymphoma: Prognostic Factors, Conventional Therapies | 2012 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy | 2012 |
Other Publication | LANCET ONCOLOGY | Autologous haemopoietic stem | 2011 |
Other Publication | Hari, P., Pasquini, M. C., Logan, B. R., Stadtmauer, E. A., Krishnan, | Immunoglobulin Free Light Chain (FLC) and Heavy Chain | 2011 |
Other Publication | JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning | 2011 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Adoptive Immunotherapy with Cytokine | 2011 |
Other Publication | HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment | 2011 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Autologous versus Reduced | 2011 |
Other Publication | Mueller, A. M., Kohrt, H. E., Laport, G. G., Negrin, R. S., Cha, S., W | LONG-TERM FOLLOW-UP OF METASTATIC BREAST CANCER PATIENTS RECEIVING HIGHLY PURIFIED AUTOLOGOUS | 2011 |
Other Publication | BONE MARROW TRANSPLANTATION | Long-term outcomes in patients with high | 2011 |
Other Publication | CURRENT OPINION IN ONCOLOGY | Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy | 2010 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Phase I/II Trial of GN-BVC | 2010 |
Other Publication | Li, L., Kohrt, H., Heish, S., Alizadeh, A., Laport, G., Shizuru, J., N | Noninvasive Prediction of Graft-Versus | 2010 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation | 2010 |
Other Publication | BONE MARROW TRANSPLANTATION | Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged | 2010 |
Other Publication | BLOOD | TLI and ATG conditioning with low risk of graft-versus | 2009 |
Other Publication | Naik, S. G., Negrin, R., Laport, G., Miklos, D., Shizuru, J., Arai, S. | Long-term outcomes of high-dose therapy using busulfan, etoposide | |
Other Publication | Kohrt, H., Turnbull, B., Laport, G., Miklos, D., Shizuru, J., Johnston | Outcomes Following Allogeneic Hematopoietic Cell Transplantation | 2008 |
Other Publication | Arai, S., Sahaf, B., Jones, C., Zhender, J., Lowsky, R., Strober, S., | Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results | 2008 |
Other Publication | Arai, S., Letsinger, R., Johnston, L., Laport, G., Lowsky, R., Miklos, | Phase I/II Trial of a Novel Gemcitabine | 2008 |
Other Publication | BLOOD | Long-term remission of Philadelphia chromosome | 2008 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma | 2008 |
Other Publication | Laport, G., Bredeson, C., Tomblyn, M. R., Kahl, B. S., Goodman, S. A., | Autologous versus reduced | |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Reduced-intensity conditioning follow by allogeneic hematopoietic cell transplantation for adult | 2008 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Controversies in lymphoma | 2008 |
Other Publication | LEUKEMIA & LYMPHOMA | Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: a concise review | 2008 |
Other Publication | Arai, S., Sheehan, K., Moore, S., Laport, G., Johnston, L., Lowsky, R. | Autologous cytokine-induced killer cells as post-transplant cellular immunotherapy | 2007 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Mantle cell lymphoma in first complete remission | 2007 |
Other Publication | Arai, S., Sahaf, B., Jones, C., Zehnder, J., Lowsky, R., Strober, S., | Rituximab infusion two months after total lymphoid irradiation-antithymocyte globulin | 2007 |
Other Publication | Arai, S., Sahaf, B., Jones, C., Zehnder, J., Lowsky, R., Strober, S., | Rituximab infusion two months after nonmyeloablative transplantation maintains B | 2006 |
Other Publication | Lowsky, R., Stockert-Goldstein, K., Laport, G., Miklos, D., Arai, S., | Clinical outcomes following allogeneic hematopoietic cell transplantation | 2006 |
Other Publication | Laport, G. G., Sheehan, K., Lowsky, R., Shizuru, J. A., Stockerl-Golds | Cytokine induced killer | 2006 |
Other Publication | Cao, T. M., Stockerl-Goldstein, K. E., Cao, P. D., Laport, G. G., Shee | High dose therapy and autologous hematopoietic cell transplantation for primary refractory diffuse | 2006 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | High-dose carmustine, etoposide | 2006 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma | 2006 |
Other Publication | Lowsky, R., Heydari, K., Sahaf, B., Shizuru, J., Laport, G., Johnston, | Haploidentical non-myeloablative allogeneic hematopoietic cell transplantation | 2005 |
Other Publication | BONE MARROW TRANSPLANTATION | Rhabdomyolysis after concomitant use of cyclosporine | 2005 |
Other Publication | NEW ENGLAND JOURNAL OF MEDICINE | Protective conditioning for acute graft-versus-host disease | 2005 |
Other Publication | Arai, S., Negrin, R., Blume, K., Johnston, L., Laport, G., Lowsky, R., | A phase I trial with extended cohort of gemcitabine | 2005 |
Other Publication | BLOOD | Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell | 2005 |
Other Publication | EXPERIMENTAL HEMATOLOGY | CD34, CD49 and CD8 cell doses do not influence engraftment | 2005 |
Other Publication | Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., S | Engraftment and survival following non-myeloablative allogeneic peripheral blood hematopoietic cell | 2004 |
Other Publication | LEUKEMIA RESEARCH | Multiple unrelated clonal abnormalities | 2004 |
Other Publication | Lowsky, R., Jones, S. D., Mitra, S., Shizuru, J. A., Laport, G. G., St | Non-myeloablative conditioning with total lymphoid irradiation (TLI) | 2003 |
Other Publication | BLOOD | Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed | 2003 |
Other Publication | Current hematology reports | Nonmyeloablative allogeneic stem cell transplantation for acute leukemia. | 2003 |
Other Publication | BONE MARROW TRANSPLANTATION | A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients | 2001 |
Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation | 2001 |
Other Publication | JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH | Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft | 2000 |
Other Publication | BONE MARROW TRANSPLANTATION | A dose escalation study of total body irradiation followed by high-dose etoposide | 2000 |
Other Publication | CYTOTHERAPY | Transplantation with low-density autologous PBSC prepared with BDS60 for women with stage II | 2000 |
Other Publication | SEMINARS IN ONCOLOGY | The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma | 1998 |
Other Publication | BONE MARROW TRANSPLANTATION | High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer | 1998 |
Other Publication | SEMINARS IN ONCOLOGY | Treatment of adult acute lymphoblastic leukemia | 1997 |
Dr. Ginna G. Laport, MD has not yet indicated the hospitals that she is affiliated with.
Internal Medicine
Years In Practice: 28 (started in 1997)
Accepts New Patients: Yes
Dr. Ginna G. Laport, MD has not yet listed the medications that she commonly prescribes.
Dr. Ginna G. Laport, MD has not yet added any information about her practice's billing policies and payment options.